vs
MESA LABORATORIES INC（MLAB）与TELOS CORP（TLS）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是TELOS CORP的1.4倍（$65.1M vs $46.8M），MESA LABORATORIES INC净利率更高（5.6% vs -34.9%，领先40.4%），TELOS CORP同比增速更快（77.4% vs 3.6%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $8.0M），过去两年TELOS CORP的营收复合增速更高（25.7% vs 5.1%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
泰洛斯公司（Telos Corporation）是一家信息技术与网络安全企业，总部位于美国弗吉尼亚州阿什本。公司主要服务对象为政府与企业客户，业务合同大部分来自美国国防部，核心客户涵盖美国军方、情报机构、民政部门以及北约盟友机构。
MLAB vs TLS — 直观对比
营收规模更大
MLAB
是对方的1.4倍
$46.8M
营收增速更快
TLS
高出73.7%
3.6%
净利率更高
MLAB
高出40.4%
-34.9%
自由现金流更多
MLAB
多$10.1M
$8.0M
两年增速更快
TLS
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $46.8M |
| 净利润 | $3.6M | $-16.3M |
| 毛利率 | 64.2% | 35.0% |
| 营业利润率 | 12.2% | -39.6% |
| 净利率 | 5.6% | -34.9% |
| 营收同比 | 3.6% | 77.4% |
| 净利润同比 | 316.6% | -74.8% |
| 每股收益（稀释后） | $0.65 | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABTLS
| Q4 25 | $65.1M | $46.8M | ||
| Q3 25 | $60.7M | $51.4M | ||
| Q2 25 | $59.5M | $36.0M | ||
| Q1 25 | $62.1M | $30.6M | ||
| Q4 24 | $62.8M | $26.4M | ||
| Q3 24 | $57.8M | $23.8M | ||
| Q2 24 | $58.2M | $28.5M | ||
| Q1 24 | $58.9M | $29.6M |
净利润MLABTLS
| Q4 25 | $3.6M | $-16.3M | ||
| Q3 25 | $2.5M | $-2.1M | ||
| Q2 25 | $4.7M | $-9.5M | ||
| Q1 25 | $-7.1M | $-8.6M | ||
| Q4 24 | $-1.7M | $-9.3M | ||
| Q3 24 | $3.4M | $-28.1M | ||
| Q2 24 | $3.4M | $-7.8M | ||
| Q1 24 | $-254.6M | $-7.4M |
毛利率MLABTLS
| Q4 25 | 64.2% | 35.0% | ||
| Q3 25 | 61.5% | 39.9% | ||
| Q2 25 | 62.0% | 33.2% | ||
| Q1 25 | 61.8% | 39.8% | ||
| Q4 24 | 63.3% | 40.3% | ||
| Q3 24 | 61.3% | 13.2% | ||
| Q2 24 | 64.0% | 34.1% | ||
| Q1 24 | 62.1% | 37.0% |
营业利润率MLABTLS
| Q4 25 | 12.2% | -39.6% | ||
| Q3 25 | 7.8% | -4.8% | ||
| Q2 25 | 5.1% | -27.5% | ||
| Q1 25 | 2.4% | -29.5% | ||
| Q4 24 | 9.2% | -37.6% | ||
| Q3 24 | 6.1% | -121.4% | ||
| Q2 24 | 9.6% | -30.3% | ||
| Q1 24 | -460.6% | -28.5% |
净利率MLABTLS
| Q4 25 | 5.6% | -34.9% | ||
| Q3 25 | 4.1% | -4.1% | ||
| Q2 25 | 8.0% | -26.5% | ||
| Q1 25 | -11.4% | -28.1% | ||
| Q4 24 | -2.7% | -35.4% | ||
| Q3 24 | 5.9% | -118.0% | ||
| Q2 24 | 5.8% | -27.2% | ||
| Q1 24 | -432.2% | -24.9% |
每股收益（稀释后）MLABTLS
| Q4 25 | $0.65 | $-0.22 | ||
| Q3 25 | $0.45 | $-0.03 | ||
| Q2 25 | $0.85 | $-0.13 | ||
| Q1 25 | $-1.30 | $-0.12 | ||
| Q4 24 | $-0.31 | $-0.13 | ||
| Q3 24 | $0.63 | $-0.39 | ||
| Q2 24 | $0.62 | $-0.11 | ||
| Q1 24 | $-47.26 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $53.2M |
| 总债务越低越好 | $68.4M | — |
| 股东权益账面价值 | $186.7M | $96.0M |
| 总资产 | $434.8M | $139.9M |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资MLABTLS
| Q4 25 | $29.0M | $53.2M | ||
| Q3 25 | $20.4M | $59.0M | ||
| Q2 25 | $21.3M | $57.0M | ||
| Q1 25 | $27.3M | $57.8M | ||
| Q4 24 | $27.3M | $54.6M | ||
| Q3 24 | $24.3M | $69.8M | ||
| Q2 24 | $28.5M | $80.1M | ||
| Q1 24 | $28.2M | $93.9M |
总债务MLABTLS
| Q4 25 | $68.4M | — | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
股东权益MLABTLS
| Q4 25 | $186.7M | $96.0M | ||
| Q3 25 | $178.5M | $119.7M | ||
| Q2 25 | $172.5M | $118.4M | ||
| Q1 25 | $159.8M | $126.1M | ||
| Q4 24 | $155.2M | $127.1M | ||
| Q3 24 | $161.5M | $129.5M | ||
| Q2 24 | $150.7M | $149.1M | ||
| Q1 24 | $145.4M | $154.4M |
总资产MLABTLS
| Q4 25 | $434.8M | $139.9M | ||
| Q3 25 | $430.4M | $164.3M | ||
| Q2 25 | $435.7M | $165.0M | ||
| Q1 25 | $433.3M | $158.1M | ||
| Q4 24 | $433.3M | $158.2M | ||
| Q3 24 | $454.1M | $166.3M | ||
| Q2 24 | $440.4M | $182.4M | ||
| Q1 24 | $446.8M | $195.4M |
负债/权益比MLABTLS
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $8.0M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $8.0M |
| 自由现金流率自由现金流/营收 | 27.7% | 17.0% |
| 资本支出强度资本支出/营收 | 1.1% | 0.1% |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | $29.4M |
8季度趋势，按日历期对齐
经营现金流MLABTLS
| Q4 25 | $18.8M | $8.0M | ||
| Q3 25 | $8.2M | $9.1M | ||
| Q2 25 | $1.9M | $7.0M | ||
| Q1 25 | $12.7M | $6.1M | ||
| Q4 24 | $18.1M | $-10.5M | ||
| Q3 24 | $5.3M | $-7.1M | ||
| Q2 24 | $10.7M | $-8.0M | ||
| Q1 24 | $12.9M | $-350.0K |
自由现金流MLABTLS
| Q4 25 | $18.0M | $8.0M | ||
| Q3 25 | $7.1M | $8.7M | ||
| Q2 25 | $884.0K | $6.8M | ||
| Q1 25 | $11.9M | $6.0M | ||
| Q4 24 | $17.3M | $-12.4M | ||
| Q3 24 | $3.5M | $-7.1M | ||
| Q2 24 | $9.9M | $-8.2M | ||
| Q1 24 | $12.3M | $-447.0K |
自由现金流率MLABTLS
| Q4 25 | 27.7% | 17.0% | ||
| Q3 25 | 11.7% | 16.9% | ||
| Q2 25 | 1.5% | 19.0% | ||
| Q1 25 | 19.2% | 19.5% | ||
| Q4 24 | 27.6% | -47.0% | ||
| Q3 24 | 6.0% | -30.0% | ||
| Q2 24 | 16.9% | -28.9% | ||
| Q1 24 | 21.0% | -1.5% |
资本支出强度MLABTLS
| Q4 25 | 1.1% | 0.1% | ||
| Q3 25 | 1.8% | 0.9% | ||
| Q2 25 | 1.7% | 0.4% | ||
| Q1 25 | 1.2% | 0.4% | ||
| Q4 24 | 1.3% | 7.1% | ||
| Q3 24 | 3.1% | 0.2% | ||
| Q2 24 | 1.5% | 0.8% | ||
| Q1 24 | 0.9% | 0.3% |
现金转化率MLABTLS
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
TLS
| Security Solutions Segment | $44.8M | 96% |
| Secure Networks Segment | $1.9M | 4% |
